

HBM4EU The European Human Biomonitoring Initiative

Marike Kolossa-Gehring & team
HBM4EU Coordinator
German Environment Agency







"For the health of our citizens, our children and grandchildren, Europe needs to move towards a zero-pollution ambition.

I will put forward a cross-cutting strategy to protect citizens' health

from environmental degradation and pollution, addressing air and water quality, hazardous chemicals, industrial emissions, pesticides and endocrine disruptors."

Ursula von der Leyen,
A Union that strives for more My agenda for Europe



Biodiversity Strategy 2030

New **Circular Economy** Action
Plan

Farm to fork strategy

Chemicals strategy for sustainability

Protect citizens against dangerous chemicals with a new chemical strategy for a toxic-free environment

Zero pollution strategy

The European Green Deal

to "protect, conserve and enhance the EU's natural capital, and protect the health and well-being of citizens from environment-related risks and impacts."

Push for indicators:

Need to monitor ongoing trends in exposure!

Commission ambitions need to be **translated into policy** (co-decision with MS and EP)

Let's make HBM4EU the baseline against which progress should be evaluated!

The European Human Biomonitoring Initiative - HBM4EU

HBM4EU

5 years (2017-2021)

European Joint Programme

under Horizon 2020

Total budget: ~ 74 million €

30 countries and the European Environment Agency

120 Partner organisations

Coordinated by the German Environment Agency (UBA)



Answer open policyrelevant questions as defined by EU-Services and partner countries

Give policy makers a fast and easy access to results and data

World-wide unique approach

17/12/2020

HBM studies: Data, policy, communication



Science-based facts for policy making and risk assessment

Strengthening Risk Assessment:





Exposure data
Effect data

Report on exposure levels / monitoring data

- Delivering results for information of manifold target groups (scientists, media, general public)
- Results for voluntary risk mitigation measures

Opening doors for communication with general public

- Information about exposure sources and health impacts, recommendations for consumer decisions and behavioural choices
- Access to general public through direct contact with study participants

The network at the science policy interface

Grant Signatoriesfrom

- ~ 24 ministries and authorities
- ~ 11 research institutions
- 6 universities
- EEA


National Hubs in all partner countries

- Review national needs
- Feedback from and into HBM4EU
- Strengthen national coordination

The foundation for a sustainable HBM in Europe

→ To further improve the EU Chemicals policy

HBM4EU – A sustainable network of laboratories



Example Bisphenol A

Substance	Biomarker	Matrix (amount)	Analytical Method MDL				
Category A							
Bisphenol A	BPA	Urine (0.5 mL)	LC-MS-MS	0.02 ng/mL			
Category B							
Bisphenol S	BPS	Urine (NA)	LC-MS-MS	0.03 ng/mL			
Bisphenol F	BPF	Urine (NA)	LC-MS-MS	0.03 ng/mL			



HORIZON2020 Programme

Prioritised list of biomarkers, matrices and analytical methods for the 1st prioritisation round

Deliverable Report

D 9.2

WP9 - Laboratory analysis and quality assurance Deadline: September, 2017

Upload by Coordinator: 15 September 2017

Entity	Name of person responsible	Short name ofinstitution	Received v1.0/v1.1
Coordinator	Marike Kolossa	UBA	15.06.2017/30.08.2017
GrantSignatory	Geir Bukholm	NIPH	06.06.2017/15.08.2017
Pillar Leader	Argelia Castaño and Greet Schoeters	ISCIII VITO	15.06.2017/18.08.2017
Work Package Leader	Argelia Castaño and Marta Esteban López	ISCIII	09.06.2017/18.08.2017
Task leader	Cathrine Thomsen	NIPH	06.06.2017/15.08.2017


Responsible author	Cathrine Thomsen (NIPH)	E-mail	Cathrine.Thomsen@fhi.no
Short name of institution	1	Phone	+4721076546
Co-authors	Enrique Cequier, Octavio Pérez Luzardo, Monika Kasper- Sonnenberg, Holger Koch, Line S. Haug		

Monitoring risk of sample contamination: by field & laboratory blanc controls - Development of analytical method for direct measurement of **BPx conjugates** (WP16)

3 rounds ICI/EQUAS (organized within WP9) \rightarrow the **laboratories qualified** to analyze specific exposure biomarkers in the samples in the frame of HBM4EU:


- ✓ 22 laboratories for BPA
- √ 16 laboratories for BPS
- √ 10 laboratories for BPF

Metadata of 124 data collections



HBM4EU datasets can be searched and identified via IPCHEM https://ipchem.jrc.ec.europa.eu/RDSIdiscovery/ipchem/index.html Search by:

Chemical, Sample medium, country, time period, study population





Policy questions – and HBM4EU answers What do we learn from previous surveys

Case study on HBM indicators from DEMOCOPHES data for BPA

Exposure levels in the population [weighted geometric mean (95% CI)]:

- Children: Urinary levels BPAequivalents = 1,97 μg/L (1.91-2.15)
- Mothers: Urinary levels BPAequivalents = 1,78 μg/L (1.62-1.94)










Survey planning and harmonisation


- ✓ Established a sampling frame for Europe to align ongoing/planned studies to collect HBM data of the prioritised samples with EU wide coverage.
- ✓ Focus on specific chemicals per age group
- ✓ Samples collected in 11 different European countries
- ✓ For Bisphenols (A, S, F)
 - Adults (20-39 years)



Exposure levels: preliminary results

→ Urinary levels of BPA among EU women

Overview of BPA levels among 14 European studies collected and urine matrices -> 4250 women with available BPA measure, between 2007-2015





Wide variability in BPA exposure levels both between data collections and countries


→ several intrinsic factors could be involved based on the heterogeneity of the data collected: sampling years, analytical methods, age ranges...

Case studies on HBM data:

Exposure distributions








Geographic comparisons







Time trends in phthalates in Danish and German Young Adults between 2000 and 2017

Preliminary results from regression analyses:

- Controlled for sex, age, education, bmi, crt
- For several metabolites no differences between studies in level of concentration and trend over time
- Some indication that **regulated phthalates decrease**, less regulated do not change MEHP (DEHP, reg) OXO-MIDP/MPHP (DIDP/DPHP, subst, unreg)





- Declining trend (p < 0.01)</p>
- Studies do not differ sign.

- No sign. change
- Studies do not differ sign.

HBM Guidance values

correspond to internal exposure levels below which health risks are not expected

promote use of HBM data to facilitate communication by interpreting health impacts

derived by experts on the basis of toxicological and epidemiological data

Transparent and inclusive:
developed in consultation with
national experts (National Hubs)
and the EU Policy Board

HBM GV for the general population and/or workers have been derived

Apel P., Rousselle C., Lange R., Sissoko, F., Kolossa-Gehring M., Ougier E. (**2020**): Human biomonitoring initiative (HBM4EU) – Strategy to derive human biomonitoring guidance values (HBM-GVs) for health risk assessment, Doi: 10.1016/j.ijheh.2020.113622

HBM GV for the general population and/ or workers have been derived

Adopted within HBM4EU

- Plasticisers: 5 phthalates + Hexamoll®DINCH,
- Plastic ingredient:BPA
- Cadmium

Consultation completed

- Aprotic Solvents: NMP, NEP
- Plasticisers: BPS, BPF

Consultation coming soon

- Insecticides: Deltamethrin
- Solvents: DMF (on oing), DMAc

Planned for 2021


- Pesticides: Cyfluthrin
- Mycotoxin: Deoxynivalenol (DON)
- Mercury
- Chromium VI
- Toluene diisocyanate (TDI)

HBM4EU for better health information

David, Madlen et al. *Archives of Public Health* 78, Nr. 1 (Dezember 2020): 78. https://doi.org/10.1186/s13690-020-00460-9.

HBM4EU integrates public health and environmental health issues


 based on previous work and knowledge transfer of relevant networks




Bringing together public health and environmental health allows for better research on people's health and well-being

Mixtures in human biomonitoring

- Analyzing existing individual HBM data of multiple chemicals
- 5 case studies on mixtures and health outcomes (i.a. reproduction, cancer)
- SPECIMEn Joint Survey on Pesticide Mixtures, targeted and non-targeted HBM





How can mixture effects of human PFASs mixtures be estimated?

Target isolation of PFAS mixtures from human samples

Direct chemical extraction and biological assessment:

AU (Bonefeld-Jorgensen's lab) has developed a protocol to extract realworld PFAS from human placentas.

The extracts test for *in vitro* combined xenoestrogenic transactivity bioassays to assess biological activities of PFAS mixtures.

Relevance: The implementation of bioassays evaluating this PFAS-extract in epidemiologic studies could inform risk assessment procedures.




Figure 1. Estrogen receptor transactivity of placenta extracts tested alone.

Original publication: Determination of perfluoroalkyl substances in placenta using a simple extraction procedure suitable for exposure assessment (Talanta, 2021) *Collaboration with WP16*

^{*} Transactivity of the sample significantly different from the procedural blank.

HBM4EU to support occupational safety Tiina Santonen, Occupational chromate study

HBM4EU study on occupational chromate exposure – aimed to reply the main policy questions on Cr(VI)

Best biomarkers to assess Cr(VI)
exposure? All exposure
biomarkers showed increased
exposure of workers. RBC- and
EBC-Cr can be used to
complement U-Cr in
biomonitoring of exposure

Dermal exposure contributes to total exposure!

Further occupational studies planned for 2020-2021:

Exposure to diisocyanates

Exposures in E-waste processing



Policy questions – and HBM4EU answers

Examples from the occupational study on chromates:



HBM4EU policy question:

What is the level of exposure occupationally relevant to Cr(VI) in the EU population? What are the groups of risk?



All studied occupational groups showed higher exposure than control population, chrome platers having highest levels

HBM4EU policy question:

Has the regulation under REACH had a favorable impact (like a reduction of concentrations)?



Regardless of REACH authorization, chrome plating is still showing elevated exposure.













HBM4EU input to policy processes

Policy				
processes 2020	HBM4EU input			
Directive on the sustainable use of pesticides	HBM4EU input on pesticides			
ECHA call for evidence on PFAS	HBM4EU input on PFAS			
Farm to Fork Strategy	HBM4EU input on farm to fork strategy roadmap			
DG SANTE	Report on copper – rapid response			
EFSA	Workshop with EFSA			
Chemicals strategy	Letter to commissioners HBM4EU input on chemicals strategy for sustainability roadmap			

Rapid Response Mechanism

Background:

DG Sante

Request

Information about Cu compounds

(context: renewal of approval of Cu compounds as active substances used as plant protection products)

Process:

Oct 2018
Request by DG
SANTE

MB mobilised expertise within HBM4EU consortium HBM4EU Consortium asked by NH to share HBM data on Cu Teleconference meeting between T4.3 partners + EFSA + DG SANTE April 2020 Submission of the response document

Outcome:










35 HBM data collections from 13 countries:
33 for the general population
2 for occupational population



HBM4EU letter to Commissioners

Main point: Europe needs a human biomonitoring surveillance system grounded in European Union legislation

Support for:

- "One substance one assessment"
- Approaches to explicitly avoid regrettable substitution
- Chemical grouping
- Combined exposure determination



HORIZON2020 Programme Contract No. 733032 HBM4EU

Frans Timmermans, Vice-President of the European Commission

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth

Virginijus Sinkevičius, Commissioner for the Environment, Oceans and Fisheries

Stella Kyriakidis, Commissioner for Health and Food safety

Thierry Breton, Commissioner for the Internal Market, Industry, Entrepreneurship and SMEs

Nicolas Schmit, Commissioner for Jobs and Social Rights

European Commission

B-1049 Brussels


Paris 21/08/2020

Open Letter: Human Biomonitoring as a tool to support Europe's Chemical Strategy for Sustainability

Dear Vice-President Timmermans, Commissioner Gabriel, Commissioner Sinkevičius, Commissioner Kyriakides, Commissioner Breton and Commissioner Schmit,

We write on behalf of <u>HBM4EU</u> to express our strong support for the forthcoming Chemicals Strategy for Sustainability and the zero pollution agenda in the frame of the European Green Deal.

Risk assessment: added value



Traditional approaches: HBM, linking internal and external exposure

Innovative approaches: systematically (via AOPs) identifying effect markers, *targeted and non-targeted* HBM, development of new methods-and application in the mixture study SPECIMEn (n= 100 Children)



Communication tools (lead EEA)



Published: 21/01/2020

HBM4EU Website
Leaflet
Newsletter
Online Library
Scoping documents
Introduction for
Stakeholders
Deliverables
Fact Sheets
Introductory video











Thank you very much for your attention!

Our gratitude to the HBM4EU Management Board and to all our wonderfull partners!



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032.